Clinical TrialsSearch results
Number of results: 1194
- Recruitment status
- Title of the study
- Health Condition
- Primary sponsor
- Date of registration
Recruiting
- Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With a Complicated Regimen
- HIV-1-Infection
- Watanabe Takanobu
- 2024-01-19
Recruiting
- Development of an algorithm for trauma treatment strategy using CT images.
- Trauma
- Okada Naoki
- 2024-01-19
Not yet recruiting
- Role of vascular inflammation in femoral popliteal artery lesions
- LEAD
- Fukuda Daiju
- 2024-01-13
Recruiting
- The First Clinical Trial of Bacteriophage Therapy in Patients wtih Acne Vulgaris
- Acne Vulgaris
- Tsuruta Daisuke
- 2024-01-12
Recruiting
- A study on the grading of intraductal papillary mucinous tumor (IPMN) by esophagogastroduodenoscopy using a synthetic human secretin preparation and a specialized catheter
- Intraductal papillary mucinous neoplasm
- Shinichi Yachida
- 2024-01-12
Recruiting
- Clinical Trial Comparing the Cooling Effect of Different Balloon Sizes of Cryoballoon Ablation in Patients with Paroxysmal Atrial Fibrillation
- paroxysmal atrial fibrillation
- Miyamoto Koji
- 2024-01-09
Recruiting
- An exploratory clinical study using a wearable device and smartphone application for heart failure
- Chronic Heart Failure
- Miyagawa Shigeru
- 2024-01-09
Completed
- DS-7830A PHASE 1 STUDY-A study to assess the safety,tolerability, and pharmacokinetics of single and multiple oral administration of DS-7830a in Japanese healthy adults, and to evaluate the effect of food (high-fat and low-fat meal) on the pharmacokinetics of orally administrated DS-7830a in Japanese healthy adults-
- major depressive disorder
- Inoguchi Akihiro
- 2023-12-22
Recruiting
- Survey of dotinurad use in hyperuricemic patients with impaired renal function
-A retrospective observational study-
- Patients with hyperuricemia (renal function as eGFR category G1-G5)
- Shimazu keiji
- 2023-12-21
Recruiting
- Patient reported preference for subcutaneous MK-3475-A over intravenous pembrolizumab formulation in multiple tumor types
- Early-stage or advanced/metastatic solid tumors
- Tanaka Yoshiyuki
- 2023-12-19